Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Thumbnail

New imaging agent for chronic diseases earns praise following first in-human trial

The PET radiotracer targets inflammation and quickly clears from the bloodstream, nuclear medicine experts reported in a new study.

Thumbnail

New PET agent may ‘revolutionize’ diagnostic workup for numerous diseases

Molecular Targeting Technologies, a privately owned biotech company, recently won a patent for its 18F-fluroglucaric acid necrosis agent.

Thumbnail

Amid COVID-19 vaccine rollout, providers may slowly resume ventilation/perfusion lung scans

SNMMI said V/Q scans can be increasingly incorporated as a normal part of the workup of suspected pulmonary embolism.

Thumbnail

New guide helps clinicians better diagnose coronary artery disease using PET myocardial blood flow

SNMMI and ASNC developed their step-by-step document to be a somewhat easy read, sharing the 20-page statement free online.

vaccine syringe covid-19 coronavirus

Molecular imaging group shares updates for managing COVID-19 vaccine effects on PET/CT exams

Lymph node swelling has been reported in up to 16% of patients who've received either the Pfizer/BioNTech or Moderna shots, SNMMI noted.

Novel radiotracer is safe, effective for treating neuroendocrine tumors

NET diagnoses are rare but have increased by 6.4-fold between 1973 and 2012, researchers reported in the Journal of Nuclear Medicine.

Thumbnail

New startup Aktis Oncology debuts with $72M in financing for novel radiopharmaceuticals

Big-name players Novartis and Bristol Myers Squibb were among those that participated in the company's series A round of financing.

Thumbnail

Immuno-PET may enhance cancer treatment decisions, predict response to therapy

National Institutes of Health and Memorial Sloan Kettering Cancer Center researchers shared their findings in the March issue of the Journal of Nuclear Medicine.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.